TuHURA Biosciences, Inc./NV
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TUHURA BIOSCIENCES, INC. | ||
| Dated: March 31, 2026 | By: | /s/ James A. Bianco |
|---|---|---|
| Name: | James A. Bianco, M.D. | |
| Title: | President and Chief Executive Officer |
KNOW ALL THESE PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James A. Bianco, M.D. and Dan Dearborn and each of them, jointly and severally, his attorneys-in-fact, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each said attorneys-in-fact or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ James A. Bianco | President, Chief Executive Officer and Director (Principal Executive Officer) | March 31, 2026 |
| James A. Bianco, M.D.Chief Executive Officer | ||
| /s/ Dan Dearborn | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 31, 2026 |
| Dan DearbornChief Financial Officer | ||
| /s/ James Manuso | Director | March 31, 2026 |
| James Manuso, Ph.D. | ||
| /s/ Alan List | Director | March 31, 2026 |
| Alan List, M.D. | ||
| /s/ George Ng | Director | March 31, 2026 |
| George Ng | ||
| /s/ Robert Hoffman | Director | March 31, 2026 |
| Robert Hoffman /s/ Craig Tendler______________________Craig Tendler, M.D. | Director | March 31, 2026 |
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
TuHURA Biosciences, Inc. and Subsidiaries
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 677) | F-3 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2025 and 2024 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-9 |
| Notes to the Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.